You are here
MDX-060 Receives Orphan Drug Designation for Treatment of Hodgkin's Disease
"We believe that the MDX-060 has the potential to address a serious unmet medical need, and we expect to continue to rapidly develop this antibody for patients with Hodgkin's disease," said Donald L. Drakeman, President and CEO of Medarex.
MDX-060 is a fully human antibody that targets CD30, a member of the tumor necrosis factor receptor superfamily and a molecule found on activated lymphocytes. CD30 has been found to be over-expressed in several lymphoproliferative disorders and is present on malignant cells of Hodgkin's disease (HD) and anaplastic large cell lymphoma (ALCL), as well as other CD30- positive lymphomas. Currently, Medarex is conducting an expanded dose-ranging Phase II study with MDX-060 in patients with CD30-positive lymphomas.
Of the nearly 500,000 Americans with lymphoma, 168,000 have HD. According to the American Cancer Society, in 2004 there will be approximately 7,880 new cases of Hodgkin's disease in the United States, and an estimated 1,320 people will die of the disease. The frequency of ALCL in the United States is not known, but worldwide, ALCL accounts for approximately 5% of all non-Hodgkin's lymphoma.
Source: Medarex, Inc.